Related Experiment Videos
Acquired heart disease in children
1Baylor College of Medicine, Texas Children's Hospital, Houston.
Insights
Recent research advances understanding of immune-mediated heart conditions like Kawasaki disease and rheumatic heart disease. Therapies are improving, but further research into causes and mechanisms is needed for specific treatments.
Area of Science:
- Cardiology
- Immunology
- Infectious Diseases
Background:
- Kawasaki disease, acute rheumatic fever, rheumatic heart disease, cardiomyopathy, and acquired immunodeficiency syndrome involve complex immune and genetic factors.
- Immune-mediated tissue injury in Kawasaki disease may stem from superantigen responses, leading to coronary abnormalities and increased risk of early atherosclerotic heart disease.
- Understanding genetic predispositions and viral roles in cardiomyopathy is advancing.
Purpose of the Study:
- To review recent advances in understanding the pathophysiology and treatment of several cardiovascular conditions.
- To discuss updated diagnostic criteria for Kawasaki disease and acute rheumatic fever.
- To highlight current therapeutic strategies and ongoing research for cardiomyopathy and HIV-related cardiac issues.
Main Methods:
- Review of recent scientific literature and clinical findings.
- Discussion of updated diagnostic criteria for specific diseases.
- Analysis of etiological and pathophysiological mechanisms, including immune responses, genetic factors, and viral influences.
Main Results:
- Intravenous immunoglobulin is beneficial for Kawasaki disease, though etiology requires further definition.
- Updated diagnostic criteria for Kawasaki disease and acute rheumatic fever are available.
- Angiotensin-converting enzyme inhibitors show promise in improving survival for dilated cardiomyopathy.
Conclusions:
- Further research into the etiology and pathophysiology of Kawasaki disease is crucial for targeted therapies.
- Genetic factors and streptococcal pharyngitis responses are key to understanding acute rheumatic fever.
- Cardiomyopathy management benefits from understanding viral and genetic influences, with ACE inhibitors improving outcomes in dilated forms.
Abstract:
Recent advances have been made in understanding Kawasaki disease, acute rheumatic fever and rheumatic heart disease, cardiomyopathy, and acquired immunodeficiency syndrome. Immune-mediated tissue injury in Kawasaki disease is likely caused by response to a superantigen. Persistent functional and anatomic coronary abnormalities may lead to silent ischemia and increase the risk of early atherosclerotic heart disease. Intravenous immunoglobulin therapy is clearly beneficial, but specific therapy awaits further definition of the etiology and pathophysiology of Kawasaki disease. Recently updated diagnostic criteria for Kawasaki disease and acute rheumatic fever are discussed. Advances in the understanding of genetically determined abnormal immune responses to streptococcal pharyngitis may help explain acute rheumatic fever manifestations. Further advances have been made in the elucidation of the pathophysiology of cardiomyopathy, particularly the role of viruses and genetic factors. Angiotensin-converting enzyme inhibitors appear to improve survival in dilated cardiomyopathy. Controversy regarding the possible myocardial depressant effect of zidovudine in human immunodeficiency virus infection is discussed.